- النص
- تاريخ
FDA NEWS RELEASEFor Immediate Relea
FDA NEWS RELEASE
For Immediate Release: Nov. 22, 2013
Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
En Español
FDA approves new treatment for hepatitis C virus
The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.
Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen. In clinical studies, Olysio was evaluated in combination with peginterferon-alfa and ribavirin, two drugs also used to treat hepatitis C virus infection. Olysio is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection (treatment naïve) or for whom previous treatment has not been effective (treatment experienced).
“Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
In 2011, the FDA approved Victrelis (boceprevir) and Incivek (telaprevir) for the treatment of hepatitis C. Olysio was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to available therapies.
The safety and effectiveness of Olysio were evaluated in five clinical studies of 2,026 treatment-naive and treatment-experienced participants randomly assigned to receive Olysio plus peginterferon-alfa and ribavirin or placebo plus peginterferon-alfa and ribavirin. The studies were designed to measure whether a participant’s hepatitis C virus was no longer detected in the blood at least 12 weeks after finishing treatment (sustained virologic response), suggesting a participant’s infection had been cured.
Results showed 80 percent of treatment-naive participants given Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response, compared to 50 percent of participants receiving peginterferon-alfa and ribavirin alone. In one of the studies with treatment-experienced participants whose infection returned (prior relapsers), 79 percent receiving Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response compared to 37 percent of participants receiving peginterferon-alfa and ribavirin alone.
Another study examined Olysio’s safety and effectiveness in treatment-experienced participants, including prior relapsers, those who partially responded to prior therapy (partial responders) and those who did not respond to prior therapy (null responders). Adding Olysio improved response rates in each of these subgroups compared to peginterferon-alfa and ribavirin alone.
A reduction in Olysio’s effectiveness was observed in participants infected with the genotype 1a hepatitis C virus with an NS3 Q80K polymorphism, a strain of the hepatitis C virus commonly found in the United States. Olysio’s drug label includes a recommendation to screen for the presence of the strain prior to beginning therapy and to consider alternative therapy if the strain is detected.
The most common side effects reported in clinical study participants treated with Olysio in combination with peginterferon-alfa and ribavirin were rash (including photosensitivity), itching (pruritis) and nausea. Serious photosensitivity reactions resulting in hospitalization were reported. Patients will be advised to limit sun exposure and to use sun protective measures during treatment with Olysio in combination with peginterferon alfa and ribavirin. Olysio should not be used alone to treat chronic hepatitis C infection.
Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J. Victrelis is marketed by Whitehouse Station, N.J.-based Merck, and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.
For more information:
FDA: Approved Drugs: Questions and Answers
For Immediate Release: Nov. 22, 2013
Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
En Español
FDA approves new treatment for hepatitis C virus
The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.
Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen. In clinical studies, Olysio was evaluated in combination with peginterferon-alfa and ribavirin, two drugs also used to treat hepatitis C virus infection. Olysio is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection (treatment naïve) or for whom previous treatment has not been effective (treatment experienced).
“Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
In 2011, the FDA approved Victrelis (boceprevir) and Incivek (telaprevir) for the treatment of hepatitis C. Olysio was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to available therapies.
The safety and effectiveness of Olysio were evaluated in five clinical studies of 2,026 treatment-naive and treatment-experienced participants randomly assigned to receive Olysio plus peginterferon-alfa and ribavirin or placebo plus peginterferon-alfa and ribavirin. The studies were designed to measure whether a participant’s hepatitis C virus was no longer detected in the blood at least 12 weeks after finishing treatment (sustained virologic response), suggesting a participant’s infection had been cured.
Results showed 80 percent of treatment-naive participants given Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response, compared to 50 percent of participants receiving peginterferon-alfa and ribavirin alone. In one of the studies with treatment-experienced participants whose infection returned (prior relapsers), 79 percent receiving Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response compared to 37 percent of participants receiving peginterferon-alfa and ribavirin alone.
Another study examined Olysio’s safety and effectiveness in treatment-experienced participants, including prior relapsers, those who partially responded to prior therapy (partial responders) and those who did not respond to prior therapy (null responders). Adding Olysio improved response rates in each of these subgroups compared to peginterferon-alfa and ribavirin alone.
A reduction in Olysio’s effectiveness was observed in participants infected with the genotype 1a hepatitis C virus with an NS3 Q80K polymorphism, a strain of the hepatitis C virus commonly found in the United States. Olysio’s drug label includes a recommendation to screen for the presence of the strain prior to beginning therapy and to consider alternative therapy if the strain is detected.
The most common side effects reported in clinical study participants treated with Olysio in combination with peginterferon-alfa and ribavirin were rash (including photosensitivity), itching (pruritis) and nausea. Serious photosensitivity reactions resulting in hospitalization were reported. Patients will be advised to limit sun exposure and to use sun protective measures during treatment with Olysio in combination with peginterferon alfa and ribavirin. Olysio should not be used alone to treat chronic hepatitis C infection.
Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J. Victrelis is marketed by Whitehouse Station, N.J.-based Merck, and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.
For more information:
FDA: Approved Drugs: Questions and Answers
0/5000
بيان صحفي من إدارة الأغذية والعقاقيرمن أجل الإفراج الفوري: 22 نوفمبر 2013استفسارات وسائل الإعلام: ستيفاني ياو، stephanie.yao@fda.hhs.gov 301-796-0394، استفسارات المستهلك: 888-معلومات-هيئة التنمية الحرجية.الإسبانية enالهيئة توافق على علاج جديد لفيروس التهاب الكبد الوبائيالولايات المتحدة إدارة الأغذية والعقاقير المعتمدة اليوم أوليسيو (سيميبريفير)، علاج جديد لعلاج العدوى بفيروس التهاب الكبد الوبائي المزمن.التهاب الكبد الوبائي هو مرض فيروسي يسبب التهاب الكبد التي يمكن أن تؤدي إلى تضاؤل وظيفة الكبد أو فشل الكبد. معظم الناس المصابين بفيروس التهاب الكبد C قد لا تظهر أعراض للمرض حتى يصبح تلف الكبد الظاهر، الذي قد يستغرق عدة سنوات. معظم هؤلاء الناس ثم انتقل إلى وضع المزمن التهاب الكبد جيم كما سيضع بعض تندب وضعف في وظائف الكبد (تليف الكبد) على مدى سنوات عديدة، الأمر الذي يمكن أن يؤدي إلى مضاعفات مثل النزيف، واليرقان (مصفر العينين أو الجلد)، تراكم السوائل في البطن أو التهابات الكبد السرطان. طبقاً لمراكز مراقبة الأمراض والوقاية، الأميركيين حوالي 3.2 مليون مصابون بفيروس التهاب الكبد الوبائي.أوليسيو هو مثبط البروتياز أن كتل بروتين محددة يلزم بفيروس التهاب الكبد C للنسخ المتماثل. أنها ستستخدم كعنصر من عناصر نظام الجمع بين العلاج المضاد للفيروسات. في الدراسات السريرية، تم تقييم أوليسيو في تركيبة مع peginterferon alfa وريبافيرين، اثنين من العقاقير كما يستخدم لعلاج العدوى بفيروس التهاب الكبد الوبائي. أوليسيو هو مخصص للبالغين مع تعويض مرض الكبد (كبد مريضة لا يزال يعمل،) بما في ذلك تليف الكبد، الذين لم يتلقوا العلاج للعدوى (المعاملة السذاجة) أو أجله السابق العلاج لم يكن فعالاً (العلاج من ذوي الخبرة).وقال "أوليسيو هو مثبط البروتياز التي وافقت عليها إدارة الأغذية والعقاقير الثالثة لعلاج العدوى بفيروس التهاب الكبد الوبائي المزمن، وتوفر المهنيين الصحيين والمرضى بعلاج جديد وفعال لهذا المرض الخطير،" إدوارد كوكس، العضو المنتدب، مدير "مكتب المنتجات المضادة للميكروبات" في مركز لإدارة الأغذية والعقاقير "المخدرات التقييم" والبحث.في عام 2011، وافقت إدارة الأغذية والعقاقير Victrelis (بوسيبريفير) وإينسيفيك (تيلابريفير) لعلاج التهاب الكبد جيم أوليسيو واستعرضت تحت أولوية مراجعة البرنامج إدارة الأغذية والعقاقير، الذي يوفر لاستعراض معجل للعقاقير التي، إذا وافق، وسيوفر العلاج آمنة وفعالة عند لا مرض العلاج البديل موجود، أو توفر تحسنا كبيرا مقارنة بالعلاجات المتاحة.تم تقييم سلامة وفعالية أوليسيو في خمس دراسات سريرية 2,026 السذاجة العلاج والعلاج--خبرة المشاركين عشوائياً لتلقي أوليسيو بالإضافة إلى peginterferon alfa وريبافيرين أو الغفل بالإضافة إلى peginterferon ألفا وريبافيرين. الدراسات التي صممت لقياس ما إذا كان لم يعد الكشف عن فيروس التهاب الكبد الوبائي مشارك في الدم 12 أسبوعا على الأقل بعد الانتهاء من العلاج (المطرد استجابة الفيرولوجية)، مما يوحي بالإصابة بأحد المشتركين قد شُفي.وأظهرت نتائج 80 في المئة مشاركين المعاملة السذاجة نظراً أوليسيو بالإضافة إلى peginterferon alfa وريبافيرين تحقق استجابة الفيرولوجية المطرد، بالمقارنة مع 50 في المائة المشتركين تلقي peginterferon alfa وريبافيرين وحدها. في إحدى الدراسات التي أجريت مع المشاركين خبرة في علاج العدوى التي عادت (ريلابسيرس السابقة)، حققت 79 في المائة تلقي أوليسيو بالإضافة إلى peginterferon alfa وريبافيرين المطرد استجابة الفيرولوجية بالمقارنة مع 37 في المئة مشاركين تلقي peginterferon alfa وريبافيرين وحدها.درست دراسة أخرى أوليسيو في سلامة وفعالية في العلاج--خبرة المشاركين، بما في ذلك ريلابسيرس مسبق، وأولئك الذين استجابوا جزئيا للعلاج السابقة (المستجيبين جزئية) وأولئك الذين لم يستجيبوا للمعالجة المسبقة (null المستجيبين). إضافة أوليسيو تحسنت معدلات الاستجابة في كل من هذه المجموعات الفرعية مقارنة peginterferon alfa وريبافيرين وحدها.ولوحظ انخفاضا في الفعالية في أوليسيو في المشاركين المصابين بفيروس التهاب الكبد الوبائي 1a النمط الوراثي مع تعدد الأشكال NS3 Q80K، سلالة من فيروس التهاب الكبد الوبائي شائع في الولايات المتحدة. المخدرات تسمية أوليسيو يتضمن توصية الشاشة لوجود السلالة قبل بداية العلاج، والنظر في العلاج البديل إذا تم الكشف عن السلالة.الآثار الجانبية الأكثر شيوعاً التي ذكرت في المشاركين في الدراسة السريرية تعامل مع أوليسيو في تركيبة مع peginterferon ألفا وكانت ريبافيرين طفح جلدي (بما في ذلك الحساسية الضيائية)، الحكة (الحكة) والغثيان. أبلغ عن تفاعلات حساسية خطيرة أسفر عن العلاج في المستشفيات. وسوف أبلغ المرضى الحد من التعرض لأشعة الشمس، واستخدام تدابير واقية الشمس أثناء العلاج مع أوليسيو في تركيبة مع peginterferon alfa وريبافيرين. ينبغي عدم استخدام أوليسيو وحدة لعلاج العدوى المزمنة التهاب الكبد C.أوليسيو يتم تسويقه "المستحضرات الصيدلانية يانسن"، مقرها في راريتان، Victrelis ونيو جيرسي هو تسويقها من قبل شركة ميرك المستندة إلى محطة، ونيو جيرسي في البيت الأبيض، وهو يسوق إينسيفيك بواسطة المستندة إلى كامبريدج، ماساشوستس "ذروة المستحضرات الصيدلانية".للحصول على مزيد من المعلومات: إدارة الأغذية والعقاقير: وافقت العقاقير: أسئلة وأجوبة
يجري ترجمتها، يرجى الانتظار ..
FDA NEWS RELEASE
For Immediate Release: Nov. 22, 2013
Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
En Español
FDA approves new treatment for hepatitis C virus
The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.
Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen. In clinical studies, Olysio was evaluated in combination with peginterferon-alfa and ribavirin, two drugs also used to treat hepatitis C virus infection. Olysio is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection (treatment naïve) or for whom previous treatment has not been effective (treatment experienced).
“Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
In 2011, the FDA approved Victrelis (boceprevir) and Incivek (telaprevir) for the treatment of hepatitis C. Olysio was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to available therapies.
The safety and effectiveness of Olysio were evaluated in five clinical studies of 2,026 treatment-naive and treatment-experienced participants randomly assigned to receive Olysio plus peginterferon-alfa and ribavirin or placebo plus peginterferon-alfa and ribavirin. The studies were designed to measure whether a participant’s hepatitis C virus was no longer detected in the blood at least 12 weeks after finishing treatment (sustained virologic response), suggesting a participant’s infection had been cured.
Results showed 80 percent of treatment-naive participants given Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response, compared to 50 percent of participants receiving peginterferon-alfa and ribavirin alone. In one of the studies with treatment-experienced participants whose infection returned (prior relapsers), 79 percent receiving Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response compared to 37 percent of participants receiving peginterferon-alfa and ribavirin alone.
Another study examined Olysio’s safety and effectiveness in treatment-experienced participants, including prior relapsers, those who partially responded to prior therapy (partial responders) and those who did not respond to prior therapy (null responders). Adding Olysio improved response rates in each of these subgroups compared to peginterferon-alfa and ribavirin alone.
A reduction in Olysio’s effectiveness was observed in participants infected with the genotype 1a hepatitis C virus with an NS3 Q80K polymorphism, a strain of the hepatitis C virus commonly found in the United States. Olysio’s drug label includes a recommendation to screen for the presence of the strain prior to beginning therapy and to consider alternative therapy if the strain is detected.
The most common side effects reported in clinical study participants treated with Olysio in combination with peginterferon-alfa and ribavirin were rash (including photosensitivity), itching (pruritis) and nausea. Serious photosensitivity reactions resulting in hospitalization were reported. Patients will be advised to limit sun exposure and to use sun protective measures during treatment with Olysio in combination with peginterferon alfa and ribavirin. Olysio should not be used alone to treat chronic hepatitis C infection.
Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J. Victrelis is marketed by Whitehouse Station, N.J.-based Merck, and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.
For more information:
FDA: Approved Drugs: Questions and Answers
For Immediate Release: Nov. 22, 2013
Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
En Español
FDA approves new treatment for hepatitis C virus
The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.
Olysio is a protease inhibitor that blocks a specific protein needed by the hepatitis C virus to replicate. It is to be used as a component of a combination antiviral treatment regimen. In clinical studies, Olysio was evaluated in combination with peginterferon-alfa and ribavirin, two drugs also used to treat hepatitis C virus infection. Olysio is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection (treatment naïve) or for whom previous treatment has not been effective (treatment experienced).
“Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
In 2011, the FDA approved Victrelis (boceprevir) and Incivek (telaprevir) for the treatment of hepatitis C. Olysio was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that, if approved, would provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to available therapies.
The safety and effectiveness of Olysio were evaluated in five clinical studies of 2,026 treatment-naive and treatment-experienced participants randomly assigned to receive Olysio plus peginterferon-alfa and ribavirin or placebo plus peginterferon-alfa and ribavirin. The studies were designed to measure whether a participant’s hepatitis C virus was no longer detected in the blood at least 12 weeks after finishing treatment (sustained virologic response), suggesting a participant’s infection had been cured.
Results showed 80 percent of treatment-naive participants given Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response, compared to 50 percent of participants receiving peginterferon-alfa and ribavirin alone. In one of the studies with treatment-experienced participants whose infection returned (prior relapsers), 79 percent receiving Olysio plus peginterferon-alfa and ribavirin achieved sustained virologic response compared to 37 percent of participants receiving peginterferon-alfa and ribavirin alone.
Another study examined Olysio’s safety and effectiveness in treatment-experienced participants, including prior relapsers, those who partially responded to prior therapy (partial responders) and those who did not respond to prior therapy (null responders). Adding Olysio improved response rates in each of these subgroups compared to peginterferon-alfa and ribavirin alone.
A reduction in Olysio’s effectiveness was observed in participants infected with the genotype 1a hepatitis C virus with an NS3 Q80K polymorphism, a strain of the hepatitis C virus commonly found in the United States. Olysio’s drug label includes a recommendation to screen for the presence of the strain prior to beginning therapy and to consider alternative therapy if the strain is detected.
The most common side effects reported in clinical study participants treated with Olysio in combination with peginterferon-alfa and ribavirin were rash (including photosensitivity), itching (pruritis) and nausea. Serious photosensitivity reactions resulting in hospitalization were reported. Patients will be advised to limit sun exposure and to use sun protective measures during treatment with Olysio in combination with peginterferon alfa and ribavirin. Olysio should not be used alone to treat chronic hepatitis C infection.
Olysio is marketed by Janssen Pharmaceuticals, based in Raritan, N.J. Victrelis is marketed by Whitehouse Station, N.J.-based Merck, and Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.
For more information:
FDA: Approved Drugs: Questions and Answers
يجري ترجمتها، يرجى الانتظار ..
لغات أخرى
دعم الترجمة أداة: الآيسلندية, الأذرية, الأردية, الأفريقانية, الألبانية, الألمانية, الأمهرية, الأوديا (الأوريا), الأوزبكية, الأوكرانية, الأويغورية, الأيرلندية, الإسبانية, الإستونية, الإنجليزية, الإندونيسية, الإيطالية, الإيغبو, الارمنية, الاسبرانتو, الاسكتلندية الغالية, الباسكية, الباشتوية, البرتغالية, البلغارية, البنجابية, البنغالية, البورمية, البوسنية, البولندية, البيلاروسية, التاميلية, التايلاندية, التتارية, التركمانية, التركية, التشيكية, التعرّف التلقائي على اللغة, التيلوجو, الجاليكية, الجاوية, الجورجية, الخؤوصا, الخميرية, الدانماركية, الروسية, الرومانية, الزولوية, الساموانية, الساندينيزية, السلوفاكية, السلوفينية, السندية, السنهالية, السواحيلية, السويدية, السيبيوانية, السيسوتو, الشونا, الصربية, الصومالية, الصينية, الطاجيكي, العبرية, العربية, الغوجراتية, الفارسية, الفرنسية, الفريزية, الفلبينية, الفنلندية, الفيتنامية, القطلونية, القيرغيزية, الكازاكي, الكانادا, الكردية, الكرواتية, الكشف التلقائي, الكورسيكي, الكورية, الكينيارواندية, اللاتفية, اللاتينية, اللاوو, اللغة الكريولية الهايتية, اللوكسمبورغية, الليتوانية, المالايالامية, المالطيّة, الماورية, المدغشقرية, المقدونية, الملايو, المنغولية, المهراتية, النرويجية, النيبالية, الهمونجية, الهندية, الهنغارية, الهوسا, الهولندية, الويلزية, اليورباية, اليونانية, الييدية, تشيتشوا, كلينجون, لغة هاواي, ياباني, لغة الترجمة.
- Pong
- وجع قلبي
- We're sorry, but our GMs are currently u
- انت وجع قلبي
- بروب جده
- بنتك تعرف الانجليزي
- 应该
- Is there Something very important You ha
- So i confirm your friend request
- 份
- Pong
- انتي كلامك زباله
- اقامو حفله مهرجان الالوان في الهند
- Effectively contribute
- انا صنعته يب
- Security company
- they are we going to go
- I work here In Dubai in Security company
- they are we going to go
- انت تبين راتبك
- Fast
- انت ترسلين الفلوس لفيتنام لازم يكون عندك
- they are we going to go
- لقد حققنا الكثير من التقدم في بعض المجمل
